Cargando…

Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study

INTRODUCTION: Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share similarities and are classified as spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae antibody (ASCA), anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane porin C (ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Mundwiler, Matthew L, Mei, Ling, Landers, Carol J, Reveille, John D, Targan, Stephan, Weisman, Michael H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003540/
https://www.ncbi.nlm.nih.gov/pubmed/19930665
http://dx.doi.org/10.1186/ar2866
_version_ 1782193873752162304
author Mundwiler, Matthew L
Mei, Ling
Landers, Carol J
Reveille, John D
Targan, Stephan
Weisman, Michael H
author_facet Mundwiler, Matthew L
Mei, Ling
Landers, Carol J
Reveille, John D
Targan, Stephan
Weisman, Michael H
author_sort Mundwiler, Matthew L
collection PubMed
description INTRODUCTION: Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share similarities and are classified as spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae antibody (ASCA), anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane porin C (anti-OmpC), anti-flagellin (anti-CBir1), and antineutrophil cytoplasmic antibodies (ANCA) possess clinical significance. Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls. METHODS: Serum stored from 80 AS patients and 80 control subjects was available for analysis. ASCA, anti-I2, anti-OmpC, anti-CBir1, and ANCA studies were completed on all serum samples using Enzyme-Linked Immunosorbent Assay (ELISA) methodology. The following analyses were performed: comparison of positivity based on the established values in IBD, median values, the number of subjects in each serology in the 4(th )quartile of a normal distribution, and the mean quartile sum of all the antibodies. RESULTS: There was no difference in positivity rates between AS and control groups with the established IBD values. The median anti-I2 response was significantly higher in AS than in controls (11.78 vs 7.86, p = 0.017). Significantly more AS patients had quartile scores of 4 for the following antibody responses: ASCA IgG (26% vs 13%, p = 0.016, OR = 2.49, CI 1.168 - 5.313), ASCA IgG and IgA (27% vs 12%, p = 0.006, OR = 2.9, CI: 1.342 - 6.264), and anti - I2 (25% vs 14%, p = 0.0424, OR = 2.15, CI: 1.018 - 4.538). The mean quartile sum of the antibody responses was elevated in AS patients when ANCA was excluded (10.526 vs 9.519, p = 0.03). When ANCA was included, this difference lost significance. CONCLUSIONS: The data from this pilot study points towards mucosal dysregulation as an important pathway in AS. We were able to demonstrate that anti-I2 could play a pathologic role in AS. The elevated mean total antibody response being significant only with ANCA exclusion is consistent with the histopathological evidence that intestinal inflammation in AS is similar to Crohn's disease. To better define the roles of these antibodies in AS, larger studies with more precisely defined patient characteristics are required.
format Text
id pubmed-3003540
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30035402010-12-18 Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study Mundwiler, Matthew L Mei, Ling Landers, Carol J Reveille, John D Targan, Stephan Weisman, Michael H Arthritis Res Ther Research Article INTRODUCTION: Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share similarities and are classified as spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae antibody (ASCA), anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane porin C (anti-OmpC), anti-flagellin (anti-CBir1), and antineutrophil cytoplasmic antibodies (ANCA) possess clinical significance. Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls. METHODS: Serum stored from 80 AS patients and 80 control subjects was available for analysis. ASCA, anti-I2, anti-OmpC, anti-CBir1, and ANCA studies were completed on all serum samples using Enzyme-Linked Immunosorbent Assay (ELISA) methodology. The following analyses were performed: comparison of positivity based on the established values in IBD, median values, the number of subjects in each serology in the 4(th )quartile of a normal distribution, and the mean quartile sum of all the antibodies. RESULTS: There was no difference in positivity rates between AS and control groups with the established IBD values. The median anti-I2 response was significantly higher in AS than in controls (11.78 vs 7.86, p = 0.017). Significantly more AS patients had quartile scores of 4 for the following antibody responses: ASCA IgG (26% vs 13%, p = 0.016, OR = 2.49, CI 1.168 - 5.313), ASCA IgG and IgA (27% vs 12%, p = 0.006, OR = 2.9, CI: 1.342 - 6.264), and anti - I2 (25% vs 14%, p = 0.0424, OR = 2.15, CI: 1.018 - 4.538). The mean quartile sum of the antibody responses was elevated in AS patients when ANCA was excluded (10.526 vs 9.519, p = 0.03). When ANCA was included, this difference lost significance. CONCLUSIONS: The data from this pilot study points towards mucosal dysregulation as an important pathway in AS. We were able to demonstrate that anti-I2 could play a pathologic role in AS. The elevated mean total antibody response being significant only with ANCA exclusion is consistent with the histopathological evidence that intestinal inflammation in AS is similar to Crohn's disease. To better define the roles of these antibodies in AS, larger studies with more precisely defined patient characteristics are required. BioMed Central 2009 2009-11-23 /pmc/articles/PMC3003540/ /pubmed/19930665 http://dx.doi.org/10.1186/ar2866 Text en Copyright ©2009 Mundwiler et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mundwiler, Matthew L
Mei, Ling
Landers, Carol J
Reveille, John D
Targan, Stephan
Weisman, Michael H
Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
title Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
title_full Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
title_fullStr Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
title_full_unstemmed Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
title_short Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
title_sort inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003540/
https://www.ncbi.nlm.nih.gov/pubmed/19930665
http://dx.doi.org/10.1186/ar2866
work_keys_str_mv AT mundwilermatthewl inflammatoryboweldiseaseserologiesinankylosingspondylitispatientsapilotstudy
AT meiling inflammatoryboweldiseaseserologiesinankylosingspondylitispatientsapilotstudy
AT landerscarolj inflammatoryboweldiseaseserologiesinankylosingspondylitispatientsapilotstudy
AT reveillejohnd inflammatoryboweldiseaseserologiesinankylosingspondylitispatientsapilotstudy
AT targanstephan inflammatoryboweldiseaseserologiesinankylosingspondylitispatientsapilotstudy
AT weismanmichaelh inflammatoryboweldiseaseserologiesinankylosingspondylitispatientsapilotstudy